Results 11 to 20 of about 2,389,723 (301)

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy

Drugs in Context, 2018
Diabetes is a major cause of visual impairment among workingage adults in the United States. The proliferative form of diabetic retinopathy is associated with severe vision loss (acuity
Yue Zhao, Rishi P Singh
doaj   +2 more sources

Assessment of anti-VEGF intravitreal injection effects on murine neonatal Schlemm’s canal morphology [PDF]

Scientific Reports
Anti-VEGF intravitreal injections are the standard treatment for retinopathy of prematurity (ROP). Schlemm’s canal, essential for regulating the conventional aqueous humor outflow pathway, is still in development in premature infants.
Gabriella D. Hartman, Amirhesam Afsharpour, Sean M. Martin, Dawei Qu, Stuart W. Tompson, Kamakshi Sishtla, Kristina N. Whisenhunt, Anbukkarasi Muniyandi, Timothy W. Corson, Terri L. Young   +9 more
doaj   +2 more sources

Human Platelets Take up Anti-VEGF Agents [PDF]

Journal of Ophthalmology, 2021
Purpose. Growing evidence suggests different systemic exposure of anti-vascular endothelial growth factor (anti-VEGF) agents with repeated intravitreal application.
B. Sobolewska, B. Fehrenbacher, P. Münzer, H. Kalbacher, S. Geue, Konstantinos Stellos, M. Schaller, F. Ziemssen   +7 more
doaj   +6 more sources

Anti-VEGF– and anti-VEGF receptor–induced vascular alteration in mouse healthy tissues [PDF]

Proceedings of the National Academy of Sciences, 2013
Systemic therapy with anti-VEGF drugs such as bevacizumab is widely used for treatment of human patients with various solid tumors. However, systemic impacts of such drugs in host healthy vasculatures remain poorly understood. Here, we show that, in mice, systemic delivery of an anti-VEGF or an anti–VEGF receptor (VEGFR)-2 neutralizing antibody caused ...
Y. Yang, Y. Zhang, Z. Cao, H. Ji, X. Yang, H. Iwamoto, E. Wahlberg, T. Lanne, B. Sun, Y. Cao   +9 more
openaire   +3 more sources

Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization

Biomolecules
Despite extensive use of intravitreal anti-vascular endothelial growth factor (anti-VEGF) biologics for over a decade, neovascular age-related macular degeneration (nAMD) or choroidal neovascularization (CNV) continues to be a major cause of irreversible
Yingbin Fu, Zhao Zhang, Keith A. Webster, Yannis M. Paulus   +3 more
doaj   +3 more sources

Anti-VEGF

, 2010
The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability.
Bandello F., Parodi M. B., Augustin A. J., Iacono P., Schlingemann R. O., Schmidt-Erfurth U., Verbraak F. D.   +6 more
openaire   +3 more sources

The ubiquitin-like protein FAT10 in hepatocellular carcinoma cells limits the efficacy of anti-VEGF therapy

Journal of Advanced Research
Introduction: The efficacy of anti-vascular endothelial growth factor (VEGF) therapy is limited. However, the key factors involved in limiting the efficacy of anti-VEGF therapy and the underlying mechanisms remain unclear.
Yumin Qiu, Ben Che, Wenming Zhang, A.V. Zhang, Jin Ge, Dongnian Du, Jiajuan Li, Xiaogang Peng, Jianghua Shao   +8 more
doaj   +3 more sources

Anti-VEGF drugs: evidence for effectiveness

Community Eye Health Journal, 2014
Anti-vascular endothelial growth factors (anti-VEGF) are targeted biological drugs (e.g. monoclonal antibodies) that prevent the growth of new vessels by inhibiting VEGF.
Jennifer Evans , Gianni Virgili
doaj   +1 more source

Mechanistic insights into the heterogeneous response to anti‐VEGF treatment in tumors

Computational and Systems Oncology, 2021
Vascular endothelial growth factor (VEGF) is a strong promoter of angiogenesis in tumors, and anti‐VEGF treatment, such as a humanized antibody to VEGF, is clinically used as a monotherapy or in combination with chemotherapy to treat cancer patients ...
Ding Li, Stacey D. Finley
doaj   +1 more source

Effect of Alternate Treatment with Intravitreal Corticosteroid and Anti-VEGF for Macular Edema Secondary to Retinal Vein Occlusion

Journal of Ophthalmology, 2021
Purpose. To evaluate whether treatment with intravitreal corticosteroid and anti-vascular endothelial growth factor (VEGF) injections alternately can improve treatment outcomes of macular edema (ME) caused by retinal vein occlusion (RVO). Methods.
Young Hwan Bae, Seong Mi Kim, Jin Young Kim, So Hyun Bae, Hakyoung Kim, Dae Joong Ma   +5 more
doaj   +1 more source